INMB - Latest News
INmune Bio, Inc. (INMB), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $44.7M. Beta to the broader market is 0.90.
The article list below shows the most recent INMB headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent INMB Headlines
INmune Bio to Attend the 2026 Maxim Growth Summit
globenewswire.com - Oct 6, 2026
BOCA RATON, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc.
INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
globenewswire.com - Sep 14, 2026
Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commerci
INmune Bio to Present at the H.C. Wainwright Global Investment Conference
globenewswire.com - Sep 9, 2026
The on-demand presentation will be available on September 11, 2026, at 7:00 A. M.
INmune Bio: CORDStrom In The Lead After Signs Of UK Regulatory Alignment
seekingalpha.com - Aug 28, 2026
INmune Bio is significantly undervalued, with Ebstrocel for RDEB driving a compelling investment thesis amid regulatory alignment and a $67M market ca
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
globenewswire.com - Aug 26, 2026
Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB Filings support a planned EU MAA in Q1 2027
How News Affects INMB Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track INMB's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked INMB news questions
- What is the latest INMB news headline?
- The most recent INMB headline (Oct 6, 2026) is "INmune Bio to Attend the 2026 Maxim Growth Summit". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the INMB news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What INMB news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual INMB options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.